FHIR Cross-Version Extensions package for FHIR R4 from FHIR R5
0.0.1-snapshot-2 - informative International flag

FHIR Cross-Version Extensions package for FHIR R4 from FHIR R5 - Version 0.0.1-snapshot-2. See the Directory of published versions

CodeSystem: Substance Admin Substitution

Official URL: http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution Version: 2.1.0
Standards status: Informative Maturity Level: 0 Computable Name: SubstanceAdminSubstitution

Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.

This Code system is referenced in the content logical definition of the following value sets:

Properties

This code system defines the following properties for its concepts

NameCodeURITypeDescription
Specializes Specializes Coding The child code is a more narrow version of the concept represented by the parent code. I.e. Every child concept is also a valid parent concept. Used to allow determination of subsumption. Must be transitive, irreflexive, antisymmetric.
Generalizes Generalizes Coding Inverse of Specializes. Only included as a derived relationship.
internalId internalId http://terminology.hl7.org/CodeSystem/utg-concept-properties#v3-internal-id code The internal identifier for the concept in the HL7 Access database repository.
Not Selectable notSelectable http://hl7.org/fhir/concept-properties#notSelectable boolean Indicates that the code is abstract - only intended to be used as a selector for other concepts
Status status http://hl7.org/fhir/concept-properties#status code Designation of a concept's state. Normally is not populated unless the state is retired.

Concepts

This case-sensitive code system http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution defines the following codes in a Is-A hierarchy:

LvlCodeDisplayDefinitioninternalIdNot SelectableStatus
1 _ActSubstanceAdminSubstitutionCode ActSubstanceAdminSubstitutionCode

Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.

 21284 true active
2   E equivalent

Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.

 23107 active
3     EC equivalent composition

Description:

Substitution occurred or is permitted with another product that is a:

  • pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester
  • pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration

Examples:

  • Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate
  • Pharmaceutical equivalent: Lisonpril for Zestril
 23108 active
4       BC brand composition

Description:

Substitution occurred or is permitted between equivalent Brands but not Generics

Examples:

  • Zestril for Prinivil
  • Coumadin for Jantoven
 23109 active
4       G generic composition

Description: Substitution occurred or is permitted between equivalent Generics but not Brands

Examples:

  • Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
 16623 active
3     TE therapeutic alternative

Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile.

Examples:

  • ranitidine for Tagamet
 16624 active
4       TB therapeutic brand

Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics

Examples:

  • Zantac for Tagamet
 23105 active
4       TG therapeutic generic

Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands

Examples:

  • Ranitidine for cimetidine
 23106 active
2   F formulary

Description: This substitution was performed or is permitted based on formulary guidelines.

 16625 active
2   N none

No substitution occurred or is permitted.

 16622 active